Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.
$YMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2024 | $20.00 | Overweight | Cantor Fitzgerald |
| 6/28/2024 | $21.00 | Buy | Truist |
| 5/10/2023 | $5.00 → $13.00 | Neutral → Outperform | Wedbush |
| 4/3/2023 | Buy → Neutral | Guggenheim | |
| 1/27/2023 | $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/5/2023 | Outperform → Market Perform | Cowen | |
| 12/2/2022 | $23.00 → $5.00 | Buy → Neutral | BofA Securities |
| 12/2/2022 | Buy → Neutral | BofA Securities |
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma. Under the terms of the agreement, Nobelpharma will employ its
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage of Y-mAbs Therapeutics with a rating of Buy and set a new price target of $21.00
Wedbush upgraded Y-mAbs Therapeutics from Neutral to Outperform and set a new price target of $13.00 from $5.00 previously
10-Q - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, aft
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
Jones Trading analyst Justin Walsh initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and announces Price Target of $23.
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects MSC Industrial Direct Co., Inc. (NYSE:MSM) to report quarterly earnings at $1.50 per share on revenue of $1.01 million before the opening bell, according to data from Benzinga Pro. MSC Industrial Direct shares gained 1.1% to $79.10 in the after-hours trading session. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) named Peter Pfreundschuh as Chief Financial Officer, effective June 28. Y-mAbs Therapeutics shares fell 2.3% to $11.56 in the after-hours trading session. Analysts are expecting Radius Recycling, Inc. (NASDAQ:RDUS) to post a quar
Pfreundschuh previously served as Chief Financial Officer at Voyager Therapeutics, Inc.